AR008621A1 - Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto - Google Patents

Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto

Info

Publication number
AR008621A1
AR008621A1 ARP970102813A ARP970102813A AR008621A1 AR 008621 A1 AR008621 A1 AR 008621A1 AR P970102813 A ARP970102813 A AR P970102813A AR P970102813 A ARP970102813 A AR P970102813A AR 008621 A1 AR008621 A1 AR 008621A1
Authority
AR
Argentina
Prior art keywords
procedure
preparation
carrying
compound derived
pharmaceutical composition
Prior art date
Application number
ARP970102813A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR008621A1 publication Critical patent/AR008621A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los derivados de amida succínica de la formula (I) en donde W es un grupo -CO2H o -CONHOH; R, R1 y R2 SON, cada una de ellas, hidrogeno o un residuoorgánico, R3 es el residuo de un alfa-aminoácido y R4 es un grupo orgánico, constituyen los inhibidores de metaloproteinasas de matriz (MMPs) y de laliberacion de los factores-alfa de necrosis tumoral (TNF) de las células y que resultan, en consecuencia, utiles para la prevencion, el control y eltratamiento de las enfermedades en las cuales seencuentran involucrados los MMPs o TNF. También se describe un procedimiento para llevar a cabo supreparacion y las composiciones farmacéuticas que los contienen.
ARP970102813A 1996-06-27 1997-06-26 Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto AR008621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613547.0A GB9613547D0 (en) 1996-06-27 1996-06-27 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
AR008621A1 true AR008621A1 (es) 2000-02-09

Family

ID=10796022

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102813A AR008621A1 (es) 1996-06-27 1997-06-26 Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto

Country Status (18)

Country Link
EP (1) EP0920414A1 (es)
JP (1) JP2000514043A (es)
KR (1) KR20000022534A (es)
AR (1) AR008621A1 (es)
AU (1) AU733938B2 (es)
BR (1) BR9709902A (es)
CA (1) CA2257404A1 (es)
CZ (1) CZ430398A3 (es)
EA (1) EA001432B1 (es)
GB (1) GB9613547D0 (es)
ID (1) ID17792A (es)
IL (1) IL127262A0 (es)
NO (1) NO986049L (es)
NZ (1) NZ333550A (es)
PL (1) PL330897A1 (es)
TW (1) TW460441B (es)
WO (1) WO1997049674A1 (es)
ZA (1) ZA975631B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
GB9803005D0 (en) * 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804777D0 (en) * 1998-03-07 1998-04-29 British Biotech Pharm Anti-inflammatory agents
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
GB9901863D0 (en) 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
AU764051B2 (en) 1999-03-03 2003-08-07 Procter & Gamble Company, The Alkenyl- and alkynyl-containing metalloprotease inhibitors
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ES2283589T3 (es) 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
KR20060116552A (ko) * 2005-05-10 2006-11-15 연세대학교 산학협력단 매트릭스 메탈로프로테이나제 저해제로서 엔-포르밀히드록실아민 유도체
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
CN108383804A (zh) 2009-11-12 2018-08-10 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
KR927003520A (ko) * 1990-12-03 1992-12-18 죤 에드워드 베리만 펩티딜(peptidyl) 유도체
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives

Also Published As

Publication number Publication date
KR20000022534A (ko) 2000-04-25
CZ430398A3 (cs) 1999-08-11
IL127262A0 (en) 1999-09-22
GB9613547D0 (en) 1996-08-28
AU3342297A (en) 1998-01-14
NO986049D0 (no) 1998-12-22
CA2257404A1 (en) 1997-12-31
BR9709902A (pt) 1999-08-10
EA001432B1 (ru) 2001-02-26
ID17792A (id) 1998-01-29
NO986049L (no) 1999-03-01
TW460441B (en) 2001-10-21
NZ333550A (en) 2000-07-28
EA199900057A1 (ru) 1999-06-24
EP0920414A1 (en) 1999-06-09
PL330897A1 (en) 1999-06-07
ZA975631B (en) 1998-01-30
AU733938B2 (en) 2001-05-31
WO1997049674A1 (en) 1997-12-31
JP2000514043A (ja) 2000-10-24

Similar Documents

Publication Publication Date Title
AR008621A1 (es) Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
BR9815398A (pt) Composto, composição farmacêutica, método para tratamento ou prevenção de um desordem inflamatória, método de tratamento de uma condição ou doença mediada por mmps e método de tratamento de uma condição ou doença
PE20030894A1 (es) Acridona como inhibidores de la enzima impdh
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
DE60132309D1 (de) Amin-derivate zur behandlung von apoptosis
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
AR016429A1 (es) Compuesto derivado de acido hidroxamico como inhibidores de metaloproteasa de matriz (mmp), composiciones farmaceuticas y formulaciones veterinarias, usopara la preparacion de composiciones y formulaciones, compuesto intermediario, procedimiento de preparacion del compuesto.
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
ATE280763T1 (de) Matrix-metalloproteinase-hemmer
AR004961A1 (es) Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
ES2113664T3 (es) Derivados de aminoacidos como inhibidores de la no sintasa.
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
AR007079A1 (es) Derivados de alquilaminobenzotiazol y benzoxazol , un proceso para su preparación, una composición farmacéutica que los contiene, y un proceso para preparar dicha composición
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
CO5011061A1 (es) Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen